May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
Intravitreal Triamcinolone for the Treatment of Macular Edema Due to Central Retinal Vein Occlusion
Author Affiliations & Notes
  • V. Krivosic
    Ophthalmology, Hôpital Lariboisière, Paris, France
  • M. Paques
    Ophthalmology, CHNO des XV–XX, Fondtion Rotschild, Paris, France
  • J.–F. Girmens
    Ophthalmology, CHNO des VX–XX, Paris, France
  • B. Haouchine
    Ophthalmology, Hôpital Lariboisière, Paris, France
  • A. Erginay
    Ophthalmology, Hôpital Lariboisière, Paris, France
  • P. Massin
    Ophthalmology, Hôpital Lariboisière, Paris, France
  • J. Sahel
    Ophthalmology, CHNO des XV–XX, Fondation Rotschild, Paris, France
  • A. Gaudric
    Ophthalmology, Hôpital Lariboisière, Paris, France
  • Footnotes
    Commercial Relationships  V. Krivosic, None; M. Paques, None; J. Girmens, None; B. Haouchine, None; A. Erginay, None; P. Massin, None; J. Sahel, None; A. Gaudric, None.
  • Footnotes
    Support  VK001
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 4043. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      V. Krivosic, M. Paques, J.–F. Girmens, B. Haouchine, A. Erginay, P. Massin, J. Sahel, A. Gaudric; Intravitreal Triamcinolone for the Treatment of Macular Edema Due to Central Retinal Vein Occlusion . Invest. Ophthalmol. Vis. Sci. 2005;46(13):4043.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To evaluate the efficacy of intravitreal triamcinolone acetonide (IVTA) for the treatment of macular edema (ME) due to central retinal vein occlusion (CRVO). Methods:Retrospective study included 46 eyes with perfused (22) and non perfused (24) CRVO. Visual acuity was 20/50 or worse. Four mg of triamcinolone acetonide were injected. Follow up evaluations were performed 1 month, 3 months and 6 months after each injection. Measurement of visual acuity on the Snellen chart, intraocular pressure, macular thickness using optical coherence tomography (Stratus OCT3, Zeiss, Dublin CA), and fluorescein angiography were performed at each visit. Main outcome measures were changes in visual acuity and macular thickness. Results: The perfused CRVO group included 22 eyes. Mean duration from the time of diagnosis to the IVTA was 6.4 months (1–24). Mean visual acuity improved from 20/100 at baseline to 20/50 at 3 months and 20/40 at 6 months. Eleven eyes (50%) had final visual acuity ≥ 20/40. Mean macular thickness decreased from 702 µm at baseline to 364 µm at 3 months and 318 µm at 6 months. At 3 and 6 months, ME recurred in 9 patients (40%). Seven of them were given a second injection. Reinjection criteria were improved visual acuity after the first injection, no severe adverse events, macular thickness ≥ 300 µm and visual acuity ≤ 20/50. The 2 other patients were not retreated because their visual acuity was better than 20/50. At 6 months, 13 patients (60%) maintained good visual acuity without any recurrence of ME. Seven of the 22 original patients were evaluated at 9 and 12 months. Four of them were reinjected. For the 24 eyes in the non–perfused CRVO group, mean visual acuity did not improve significantly at 3 and 6 months (20/500, 20/200 and 20/640 respectively). Mean macular thickness decreased from 770 µm at baseline to 398 µm at 3 months and 367 µm at 6 months. ME recurred in 12 eyes (50%). No reinjections were performed. No endophthalmitis or uncontrolled glaucoma occurred in either of the 2 groups Conclusions:IVTA is effective in reducing ME due to CRVO. This decrease in macular thickness only correlated with an improvement in visual acuity in perfused CRVO group. In that group, 60% of patients did not need any reinjection at 6 months and at least 42% at 12 months. Further evaluation is required to assess the rate of recurrence after 12 months and the safety of IVTA reinjection.

Keywords: corticosteroids • vascular occlusion/vascular occlusive disease • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.